Rabies is making a comeback: here's what you need to know
This week, officials in the town of Westfield, New Jersey, issued a public health alert after two reports of bites associated with a raccoon that may be infected with rabies, put the surrounding communities on high alert.
Last week, New York's Nassau County Department of Health declared an imminent public health threat in response to the ongoing spread of rabies among wild and feral-domesticated animals in the county.
'The resurgence of rabies in Nassau County, with its high population density and after nearly a decade of absence, represents a serious and evolving public health concern,' Nassau County Health Commissioner Dr. Irina Gelman said in a release. 'This declaration allows us to respond to prevent further spread and protect the health and safety of Nassau County residents.'
The resurgence comes after the county had successfully eradicated the virus since 2016. Over the last year, the department has confirmed 25 rabid animals, including raccoons and feral cats. The department noted that surveillance data shows that the virus is circulating in the area.
"Let me be clear, there is no cause for alarm, as we have not yet received any reports of human transmission,' Gelman said, according People. 'However, the time for prevention is now."
The declaration comes as health authorities in nearby Suffolk County reported two cases of rabies — the first since 2009.
But, whether or not an uptick in new cases indicate that rabies is becoming more prevalent in the region is unclear right now.
The summer season has something to do with it, Stony Brook Children's Hospital Chief of Pediatric Infectious Diseases Division Dr. Sharon Nachman told News 12 Long Island.
"It is a question of where you are and what the season is, and certainly the summertime is always associated with more bites and more worries about rabies," she said. A large number of cases has also been reported in Queens.
Around 4,000 animal rabies cases are reported each year. The animals most frequently found with rabies in the U.S. are bats, skunks, raccoons, and foxes, the Centers for Disease Control and Prevention says.
Outside of the Northeast, there has been a rise in cases linked to bats, resulting in three rabies deaths in a period of just five weeks a couple of years ago, according to the Centers for Disease Control and Prevention. In 2021, five Americans died of rabies, the largest number in a decade.
Human-caused climate change has resulted in the expansion of vampire bats' habitat, and increased the risk of rabies in domestic animals, according to scientists.
This week, Denver Animal Protection warned that the public should be cautious after two bats tested positive for the rabies virus, 9 News reported.
Still, fewer than 10 people in the U.S. die from rabies each year. That's thanks to post-exposure care and the rabies vaccine. Nearly 100,000 people are vaccinated following a possible exposure each year. Treatment is nearly 100 percent effective if you get it after an exposure.
Initial rabies symptoms are similar to the flu, including fever, headache, and muscle aches. They can progress to neurological and physical symptoms, such as delirium, a fear of water, and seizures.
To prevent the risk of infection, there are several steps people can take. Make sure pets are up to date with their vaccines, stay away from wildlife, call animal control to remove stray animals from the neighborhoods, and wash any bites or scratches immediately with soap and water after possible exposures before seeking medical attention.
'Rabies is preventable through vaccination and pet owners should remember that the best protection is to vaccinate for rabies and license all pets with the town,' Westfield officials said.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jeremy Clarkson ‘absolutely devastated' after farm suffers TB outbreak
Jeremy Clarkson has revealed his Diddly Squat farm has been rocked by a tuberculosis outbreak. The TV personality shared the 'bad news' from the location at the centre of his Prime Video series Clarkson's Farm on Thursday (31 July). 'We've gone down with TB. Everyone here is absolutely devastated,' he wrote on X/Twitter. Bovine tuberculosis or TV is an infectious respiratory disease of cattle and can also infect badgers, deer, goats and pigs. The disease is considered of the biggest challenges facing the farming industry today 'An increasing number of farm families are facing the emotional and financial hardship of a TB breakdown,' Minister for Agriculture Martin Heydon TD said in May 2025, urging for 'decisive action'. There are differing beliefs over ways of reducing the spread, with farming organisations believing it should be dealt with by exploring TB in badgers. Meanwhile, government officials believe cattle movement should be made tighter. Clarkson bought the Diddly Squat land in 2008 and, after the villager who ran the farm retired in 2019, he decided to see if he could run it himself – a venture tracked in Clarkson's Farm. More to follow
Medscape
4 hours ago
- Medscape
Metabolic Disease: When Biology Advances, but Care Lags
Metabolic diseases, including type 2 diabetes (T2D), obesity, and metabolic syndrome, are a growing threat to global public health. More than 537 million adults currently live with T2D, and this number continues to rise, especially in developing countries where sedentary lifestyles and poor diets are driving the surge. These conditions impose a substantial economic burden on health systems worldwide, particularly in resource-limited areas. These disorders disrupt energy metabolism and alter the mechanisms for generating, storing, and utilizing energy. T2D is characterized by insulin resistance and chronic hyperglycemia. Obesity exacerbates insulin resistance and triggers persistent low-grade inflammation, leading to compounded metabolic dysfunctions. Currently, 39% of adults are overweight, and 13% are classified as obese. Metabolic syndromes include abdominal obesity, hypertension, dyslipidemia, and insulin resistance, together with a significantly increased risk for cardiovascular disease and T2D. This rising prevalence is driven by population aging and unhealthy lifestyles. Nonalcoholic fatty liver disease, also known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common complication of metabolic syndrome and is among the top causes of chronic liver disease globally. Coexisting T2D, obesity, and metabolic syndrome sharply increase the risk for myocardial infarction, stroke, kidney failure, and neuropathy. This cluster leads to severe health consequences and increased costs, reinforcing the need for integrated preventive and therapeutic strategies. Therapeutic Approaches Current treatments for metabolic diseases, particularly T2D, include metformin; SGLT2 inhibitors such as empagliflozin, canagliflozin, and dapagliflozin; and GLP‑1 agonists, for example, liraglutide, semaglutide, and dulaglutide. Metformin remains the first-line therapy due to its proven efficacy, low cost, and tolerability. SGLT2 inhibitors lower blood glucose levels by increasing urinary glucose excretion and offer added benefits for weight and cardiovascular health but may increase the risk for urinary and genital infections. GLP‑1 agonists improve glycemic control and support weight loss and cardiovascular protection, although they often cause gastrointestinal side effects. Emerging therapies include dual GLP‑1/glucose-dependent insulinotropic polypeptide (GIP) agonists such as tirzepatide and triple agonists targeting GLP‑1, GIP, and glucagon, which aim to enhance efficacy, improve weight loss, and reduce dosing frequency to support better treatment adherence. Research Highlights Recent findings have reshaped the understanding and management of metabolic diseases by targeting the underlying biological mechanisms. Mitochondrial dysfunction in adipose tissue is a key contributor to insulin resistance in patients with T2D. Thus, enhancing mitochondrial biogenesis and function may offer an effective therapeutic strategy for treating these diseases. Disruption of circadian rhythms impairs energy metabolism and worsens obesity, T2D, and metabolic syndrome, supporting the use of chronotherapy by aligning meals, light exposure, and medication timing with the body's natural rhythms. A 2024 report, 'Heart Disease and Stroke Statistics,' provides comprehensive data on cardiovascular health and its link with metabolic diseases. This report underscores the importance of therapies that address both glucose regulation and subclinical vascular damage associated with metabolic conditions. A review in Frontiers in Medicine identified insulin resistance as a central factor in metabolic diseases and explored gut microbiome-based therapies for MASLD, including probiotics, prebiotics, targeted antibiotics, and fecal transplantation. Patient phenotype-based treatment was proposed to improve outcomes in T2D, aiming to tailor therapies based on individual metabolic profiles. Advances in imaging and biomarkers have been highlighted for the early detection of metabolic disorders, enabling timely intervention before the development of clinical symptoms. Therapeutic Innovations Gene therapy and gut-liver axis modulation improve insulin sensitivity and reduce liver fat in MASLD models, although safety and durability remain challenging. Dual and triple agonists targeting GLP‑1, GIP, and glucagon receptors improve glycemic control, weight loss, and cardiovascular health. These therapies may also alter gene expression through epigenetic mechanisms, thereby supporting personalized treatment approaches. Early metabolic changes are linked to vascular damage, supporting early intervention in at-risk patients. mRNA therapies delivered via lipid nanoparticles improve glucose control with fewer side effects in diabetes models. Triple agonists show superior metabolic control, weight loss, and cardiovascular benefits, with better adherence and tolerability. Future Challenges Despite recent advances in the treatment of metabolic diseases, several barriers have hindered the widespread adoption of new therapies. A recent analysis highlighted the need for long-term clinical trials to validate therapies that target mitochondrial function in humans. Similarly, the implementation of personalized chronotherapy based on circadian rhythms remains technically and clinically challenging. In cardiovascular care, early vascular damage in young individuals at metabolic risk often goes undetected, delaying preventive intervention. Microbiome-based treatments for MASLD also face limitations due to individual variability and the lack of standardized protocols. Environmental factors, such as diet and stress, can amplify gene expression linked to metabolic disorders, underscoring the need for multisectoral prevention strategies. Phenotypic classification of T2D could support personalized care, but its implementation requires resources and infrastructure that are not widely available. Advanced metabolic imaging and molecular diagnostics are still inaccessible with many limited resources, restricting early detection and personalized treatment. The long-term use of GLP-1 agonists may be limited by gastrointestinal side effects in some patients, highlighting the need for more precise therapeutic selection. Triple GLP-1/GIP/glucagon agonists show strong potential but are costly and lack data in diverse populations, limiting global rollout. High costs, investment needs for gene and mRNA therapies, gaps in medical training, and public awareness are significant barriers. Addressing these challenges requires sustainable care models and innovative financing policies. Furthermore, the ongoing training of medical personnel and public education campaigns are key to ensuring effective prevention, early diagnosis, and equitable application of recent therapeutic advances. Conclusions Advances in the understanding of mitochondrial dysfunction, circadian rhythms, and the gut microbiome are transforming the management of metabolic diseases into clinical practice. Gene therapy and mRNA-based treatments show promise for T2D, obesity, and MASLD; however, further research is required to confirm their safety, effectiveness, and long-term outcomes. Standard treatments, such as metformin, SGLT2 inhibitors, and GLP-1 agonists, remain widely used, whereas newer dual and triple agonists offer additional benefits for glycemic control, weight loss, and cardiovascular protection. Personalized medicine based on phenotypic and molecular data may improve treatment outcomes but faces logistical, technological, and economic barriers. Limited access to advanced therapies in low- and middle-income countries highlights the global equity gap, which necessitates innovative public funding and sustainable care models. Strengthening diagnostic capacity, medical education, and public awareness are key to improving prevention, early diagnosis, and treatment. A coordinated global effort involving healthcare professionals, policymakers, researchers, and communities is essential to ensure that new therapies lead to meaningful and equitable improvements in public health.
Forbes
5 hours ago
- Forbes
How A 60-Year-Old Drug Developer Built A $4.4 Billion Biotech Treating ‘Butterfly Skin Disease'
L ongtime drug developer Suma Krishnan was in her late-40s when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder in which the skin becomes as fragile as butterfly wings. In 2016, at 51, after a few months of modeling the idea and starting the process of patenting it, she and her husband Krish Krishnan, with whom she'd worked in biotech for more than a decade, cofounded Krystal Biotech. Focusing on a rare disease, with just thousands of patients in the U.S., was unusual. So, too, was shunning venture capital in favor of self-funding a biotech startup, with some $5 million they'd made mainly from previous biotech companies. But perhaps the biggest bet was the science, taking a completely new approach to a problem with a gene therapy delivered as a gel that would potentially pay off big if it succeeded, but also stood a high chance of failure. 'I had to work with the regulators because they had never seen this,' Krishnan told Forbes . 'It was completely new.' Just 18 months after launching the Pittsburgh-based company, the Krishnans took it public on the Nasdaq stock exchange. Today, Krystal has a market cap of $4.4 billion with one FDA-approved therapy, Vyjuvek, for that "butterfly skin disease,"called dystrophic epidermolysis bullosa, on the market, and other gene therapies, including for cystic fibrosis and lung cancer, in various stages of clinical development. All rely on the modified herpes simplex virus, but they have different delivery mechanisms. The company's revenue reached $291 million for 2024, up more than five-fold from $51 million in 2023. Net income surged eightfold to $89 million from $11 million in the same period. The Krishnans have a combined 12% stake in the business. Suma, the company's president of research and development, is worth some $300 million by Forbes estimates, almost entirely from her stake in the business and sales of stock over the years. Krystal's stock has been volatile: It's up more than 1,300% since the IPO, but has fallen nearly 25% over the past year. 'You have to be brave and bold to do this,' Krishnan says. 'I was never afraid of risk-taking. I never felt like I needed a stable job.' Krishnan is one of the 200 entrepreneurs and leaders on this year's Forbes' 50 Over 50 list. These women—who this year also include actress Halle Berry, on the list for her menopause-related startup; social mission-oriented investor Freada Kapor Klein; and Maria Shriver, who founded the Women's Alzheimer's Movement toward the end of her first term as first lady of California—are all generating outsized professional impact in their sixth, seventh or eighth decades. Suma Krishnan, who is now 60, grew up in Bombay where her parents struggled to raise three kids. As the middle child and a girl, Krishnan says, her mother, who married at 18, began looking for arranged marriages for her as soon as she finished college. She refused. 'I always defied it and fought it,' she says. 'I was a tough one for them. I broke all the rules.' She came to the U.S. for graduate school, getting a master's degree in organic chemistry at Villanova University. (While there, she met Krish Krishnan, who was getting his MBA at Wharton and lived nearby.) After that, she worked as a drug developer, starting at Janssen Pharmaceuticals. At New River Pharmaceuticals, she led the discovery, development and approval of Vyvanse, a blockbuster drug to treat ADHD. After European drugmaker Shire (acquired by Takeda for $62 billion in 2018) bought New River for $2.6 billion in 2007, she worked on rare diseases. Then, at Intrexon (now known as Precigen), she focused on gene therapy treatments as its head of therapeutics. She holds more than 70 patents for a variety of drugs. 'For 25, 30 years, this is all that I did,' she says. 'I am familiar with all kinds of rare diseases and where the unmet need is.' 'I was never afraid of risk-taking. I never felt like I needed a stable job.' Krystal Biotech cofounder Suma Krishnan She had an idea for a gene therapy for butterfly skin patients that could be delivered as a gel directly onto the affected skin using a modified version of the herpes simplex virus to deliver the treatment. The drug works by delivering a healthy copy of the gene that encodes a type of collagen to the skin cells, enabling healing to occur. Some 25,000 people in the United States have epidermolysis bullosa, but only around 3,000 of them have the dystrophic form of it, which is severe and for which Krystal's treatment is used. Brett Kopelan, executive director of Debra, a nonprofit for those affected by the disease, and whose daughter, now 17, was born with a severe form of it, calls it 'the worst f—-ing disease you've never heard of.' Kids with it often live with constant pain and need to be bandaged on much of their bodies; they're also susceptible to numerous other ailments, including a form of skin cancer. 'My goal is to make this a chronic, livable disease like type 2 diabetes,' says Kopelan, whose daughter uses Krystal's treatment, among others. 'We're getting really close to that, and we have Suma and Krish to thank.' When she had the idea that became Vyjuvek, there were no treatments on the market. While she was at Intrexon, that company had been working with another biotech, Fibrocell (which has since been purchased by Castle Creek), on a hospital-based therapy. 'I saw the pain and suffering,' Krishnan says. 'These kids are born with missing skin from birth and it gets worse over time. They say, 'Nobody cares about us.'' She took the idea to her husband Krish, who had been the chief operating officer at New River and Intrexon and with whom she had worked for well over a decade. They decided to develop the drug—this time on their own. Biotech was booming and lab space was impossible to find in San Francisco. Instead, they searched the country for locations, settling up in a vacant lab space in Pittsburgh, a city known more for robotics startups than biotech but where they could hire grad students from Carnegie Mellon, at first flying back and forth from their home in northern California. They shunned VC funding, raising a small amount from friends and family and telling them bluntly to think of their investment as philanthropy. 'We figured if it didn't work out, we'd shut it down,' Krishnan says. In 2017, they took the company public, raising $45 million, thanks to Krish Krishnan's network taking previous companies through their IPOs. 'It was a Mickey Mouse IPO,' he says, noting that it allowed an investor from Fidelity who'd backed his previous companies to become a shareholder. 50 Over 50: 2025 Our fifth annual list of 200 women who are redefining what's possible in life's second half. VIEW THE FULL LIST The idea of delivering gene therapy at home rather than in the hospital was both elegant and a little crazy. 'Look, honestly, as great as the idea was, when somebody comes and says, 'I want to put gene therapy in a gel on a wound at home,' it's like somebody saying today, 'I want to have a house on Mars,'' says Krish Krishnan, the company's CEO. 'Yeah, great idea, but how are you going to get there? It was that kind of idea.' Six years later, in 2023, Krystal received FDA approval for Vyjuvek—very fast for a novel gene therapy. Getting the FDA to sign off on a home-based gene therapy that would use a modified version of the herpes virus during the Covid-19 pandemic required studies that could allay any concerns about safety at a time when, as Krishnan notes, 'people were very nervous about viruses.' They set a list price of $24,250 per vial. That works out to an annual cost of $631,000 per year for an average patient who uses 26 vials, before discounts; but patients typically require fewer treatments over time as their wounds heal. Gene therapies tend to be expensive, with many costing $1 million or more. With rare disease, 'the payers are a bit more forgiving on the pricing,' Krish Krishnan says, noting that any one insurer is unlikely to have more than a few patients with the disease. 'We can show the value proposition to Blue Cross Blue Shield and they understand,' he says. Life sciences investor Dan Janney, managing partner of Alta Partners, was among the few friends who invested personally in Krystal in the early days, having met Suma and Krish through their children, who went to school together. He calls Krystal 'probably the most efficient company that I've ever been involved in' in terms of its use of capital. 'They've done a really incredible job of getting to profitability,' he says. 'As great as the idea was, when somebody comes and says, 'I want to put gene therapy in a gel on a wound at home,' it's like somebody saying today, 'I want to have a house on Mars.' Krystal Biotech cofounder Krish Krishnan Krystal's drug for the butterfly skin disease isn't the only one on the market anymore. In April, clinical-stage biotech Abeona Therapeutics (which is publicly traded with a market cap of $348 million) gained FDA approval for its own gene therapy, called Zevaskyn, which uses skin grafts from sheets of a genetically modified version of the patient's own skin cells. That treatment, which has a list price of $3.1 million, launched this summer. Having gotten the one therapy on the market in the U.S. and approval for it in Europe and Japan, Krishnan is now looking at other diseases in lung disease, cancer and eye ailments. One of the furthest along, now in phase 3 clinical studies, is for ocular complications of the skin disease they're already treating. Others, now in earlier stage clinical trials, include treatments for cystic fibrosis and for lung tumors, a particular focus of Krishnan's given the increasing prevalence of lung cancer among younger women who never smoked. In each case, Krystal's drug would deliver a healthy copy of the gene to treat the disease, though the delivery mechanisms vary, with the lung cancer therapy using a nebulizer, for example. The big question is whether Krystal can successfully expand beyond one rare disease to multiple drugs that can treat a variety of health problems using gene therapies delivered with the modified herpes virus. Krishnan's plan is to use the cash from Vyjuvek's commercial sales to fund the clinical development of those other therapies. 'We have money and we can use that to develop the rest of our pipeline products,' she says. 'The first one is always harder.' More from Forbes Forbes This AI Founder Became A Billionaire By Building ChatGPT For Doctors By Amy Feldman Forbes Meet India's Self-Made Biologics Brewmaster Billionaire By Amy Feldman Forbes How Halle Berry Became The New Face Of Menopause By Maggie McGrath Forbes How This Founder Turned A Crocs-Inspired Tote Into A $100 Million Business By Lindsey Choo
